SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations
SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of a...
Saved in:
Published in | Nature communications Vol. 14; no. 1; pp. 5171 - 11 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
24.08.2023
Nature Publishing Group Nature Portfolio |
Subjects | |
Online Access | Get full text |
ISSN | 2041-1723 2041-1723 |
DOI | 10.1038/s41467-023-40960-0 |
Cover
Abstract | SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve.
As the SARS-SoV-2 pandemic progressed and the vaccinated population increased, a number of variants of concerns that circumvented the vaccine induced immunity emerged. Here the authors compare SARS-SoV-2 mRNA vaccine responses in pregnant women and other people, characterising the antibody response and Fc functions, and potency against a range of variants of concern. |
---|---|
AbstractList | SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve.
As the SARS-SoV-2 pandemic progressed and the vaccinated population increased, a number of variants of concerns that circumvented the vaccine induced immunity emerged. Here the authors compare SARS-SoV-2 mRNA vaccine responses in pregnant women and other people, characterising the antibody response and Fc functions, and potency against a range of variants of concern. SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve.As the SARS-SoV-2 pandemic progressed and the vaccinated population increased, a number of variants of concerns that circumvented the vaccine induced immunity emerged. Here the authors compare SARS-SoV-2 mRNA vaccine responses in pregnant women and other people, characterising the antibody response and Fc functions, and potency against a range of variants of concern. SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve. Abstract SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve. SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve.SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve. |
ArticleNumber | 5171 |
Author | Redd, Andrew D. Wolf, Dana Wiener, Joshua A. Hederman, Andrew P. Wright, Peter F. Blankson, Joel N. Goetghebuer, Tessa Ariën, Kevin K. Natarajan, Harini Rottenstreich, Amihai Zarbiv, Gila Bloch, Evan M. Ackerman, Margaret E. Tobian, Aaron A. R. Marchant, Arnaud Heyndrickx, Leo |
Author_xml | – sequence: 1 givenname: Andrew P. surname: Hederman fullname: Hederman, Andrew P. organization: Thayer School of Engineering, Dartmouth College – sequence: 2 givenname: Harini surname: Natarajan fullname: Natarajan, Harini organization: Department of Immunology and Microbiology, Geisel School of Medicine at Dartmouth, Dartmouth College – sequence: 3 givenname: Leo surname: Heyndrickx fullname: Heyndrickx, Leo organization: Department of Biomedical Sciences, Institute of Tropical Medicine – sequence: 4 givenname: Kevin K. orcidid: 0000-0002-1340-4165 surname: Ariën fullname: Ariën, Kevin K. organization: Department of Biomedical Sciences, Institute of Tropical Medicine – sequence: 5 givenname: Joshua A. orcidid: 0000-0003-1054-0628 surname: Wiener fullname: Wiener, Joshua A. organization: Thayer School of Engineering, Dartmouth College – sequence: 6 givenname: Peter F. surname: Wright fullname: Wright, Peter F. organization: Department of Pediatrics, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center – sequence: 7 givenname: Evan M. orcidid: 0000-0001-8181-9517 surname: Bloch fullname: Bloch, Evan M. organization: Department of Pathology, Johns Hopkins School of Medicine – sequence: 8 givenname: Aaron A. R. surname: Tobian fullname: Tobian, Aaron A. R. organization: Department of Pathology, Johns Hopkins School of Medicine – sequence: 9 givenname: Andrew D. surname: Redd fullname: Redd, Andrew D. organization: Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health – sequence: 10 givenname: Joel N. surname: Blankson fullname: Blankson, Joel N. organization: Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine – sequence: 11 givenname: Amihai surname: Rottenstreich fullname: Rottenstreich, Amihai organization: Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center – sequence: 12 givenname: Gila surname: Zarbiv fullname: Zarbiv, Gila organization: Clinical Virology Unit, Hadassah University Medical Center – sequence: 13 givenname: Dana surname: Wolf fullname: Wolf, Dana organization: Clinical Virology Unit, Hadassah University Medical Center – sequence: 14 givenname: Tessa orcidid: 0000-0002-8809-1394 surname: Goetghebuer fullname: Goetghebuer, Tessa organization: Institute for Medical Immunology, Université libre de Bruxelles, Pediatric Department, CHU St Pierre – sequence: 15 givenname: Arnaud surname: Marchant fullname: Marchant, Arnaud organization: Institute for Medical Immunology, Université libre de Bruxelles – sequence: 16 givenname: Margaret E. orcidid: 0000-0002-4253-3476 surname: Ackerman fullname: Ackerman, Margaret E. email: margaret.e.ackerman@dartmouth.edu organization: Thayer School of Engineering, Dartmouth College, Department of Immunology and Microbiology, Geisel School of Medicine at Dartmouth, Dartmouth College |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37620337$$D View this record in MEDLINE/PubMed |
BookMark | eNqNks1u1DAUhSNUREvpC7BAltiwCfgvsbNC1QhKpUpIFNhazo0zeOSxg51MNRIPX89kKG0XFdnEcs75fHKPXxZHPnhTFK8Jfk8wkx8SJ7wWJaas5LipcYmfFScUc1ISQdnRvfVxcZbSCueHNURy_qI4ZqKmmDFxUvy5Pv92XS7Cz5KijQawXo82eGScBTsm1MagO6R9h4YwGj_m5Wjb0G2R6XsDY4ionzzsPAmNITOizZKEQo8geDDRI-vRZnLeRN06kznD5PaHpFfF8167ZM4O79Pix-dP3xdfyquvF5eL86sSKk7GEvoGA3S9roQWuqEdtKLmGATpiGakpoQDNcC7RmgGjIoWMOmlFCApkJax0-Jy5nZBr9QQ7VrHrQraqv1GiEul42jBGQXG5ENkz0Vb8UqCFBoErQ3RddPIrs4sNrMmP-jtjXbuDkiw2lWj5mpUrkbtq1E4uz7OrmFq16aDPMmo3YMoD794-0stwyYDOW8asiO8OxBi-D2ZNKq1TWCc096EKSkqKyGZrKpdxLePpKswRZ8nvFPVddVIWWXVm_uR7rL8vRtZIGcBxJBSNL3KN2JfXE5o3dO_Sx9Z_2tGh8mmLPZLE__FfsJ1C1PH79A |
CitedBy_id | crossref_primary_10_1002_bit_28826 crossref_primary_10_3390_vaccines12101089 crossref_primary_10_1038_s44298_024_00067_9 crossref_primary_10_1002_anie_202404880 crossref_primary_10_1002_ange_202404880 |
Cites_doi | 10.1016/j.cell.2021.12.046 10.1038/s41586-021-03324-6 10.1016/j.cell.2021.06.005 10.1038/s41586-020-2349-y 10.1056/NEJMoa2034577 10.3389/fimmu.2014.00520 10.1016/j.jim.2010.12.016 10.1016/j.immuni.2021.08.015 10.1016/j.celrep.2021.108890 10.1016/j.cell.2021.02.037 10.1128/mbio.03617-21 10.1016/j.jim.2012.09.007 10.1126/science.abj4176 10.1146/annurev-med-042420-113838 10.1016/j.cell.2022.01.019 10.1038/s41591-021-01540-1 10.1093/ofid/ofab143 10.1016/j.cell.2021.02.026 10.1016/j.cell.2020.02.058 10.1016/j.jim.2017.01.010 10.1126/science.1187659 10.1016/j.cell.2021.03.013 10.1056/NEJMoa2022483 10.1038/s41586-021-03791-x 10.1371/journal.ppat.1008764 10.1016/j.cell.2022.01.015 10.1126/scitranslmed.abi8631 10.1038/s41586-021-04017-w 10.1126/science.1118948 10.1056/NEJMoa2035389 10.1016/j.chom.2021.11.006 10.1126/scitranslmed.abm3151 10.1056/NEJMc2113891 10.1056/NEJMc2119912 10.1038/s41586-021-03398-2 10.4161/mabs.28808 10.1038/s41541-022-00459-z 10.1016/j.immuni.2022.01.001 10.1038/s41591-021-01294-w 10.1016/j.cell.2020.10.052 10.1038/s41591-020-0897-1 10.1016/j.xcrm.2021.100290 10.1038/s41586-021-04085-y 10.1126/sciimmunol.abj1750 10.1016/j.celrep.2020.107624 10.1038/s41591-022-01753-y 10.3389/fmed.2021.628370 10.3389/fimmu.2020.618685 10.1038/s41591-018-0161-0 10.1016/j.jim.2018.01.013 10.1038/s41586-021-03696-9 10.1056/NEJMc2119641 10.1016/j.cell.2021.03.029 10.1016/j.xcrm.2021.100355 10.1371/journal.pone.0253487 10.1016/j.immuni.2021.03.009 10.48550/arXiv.1802.03426 10.1126/sciimmunol.abo3425 10.1126/sciimmunol.abe0240 10.1126/sciimmunol.adf1421 10.1016/j.jim.2019.07.002 10.1126/scitranslmed.abb4757 10.1038/s41591-021-01488-2 10.1038/s41586-020-2456-9 10.1016/j.xpro.2021.100851 10.1126/science.abf4063 10.1126/science.abq1841 10.1016/j.chom.2022.03.029 10.7554/eLife.75228 10.1016/j.chom.2021.06.001 10.1126/scitranslmed.abn7842 10.1126/science.abn7591 10.1126/science.abd0826 10.1016/j.celrep.2022.110368 10.1016/j.cell.2020.06.025 10.15585/mmwr.mm6925a1 10.1126/scitranslmed.abm2311 |
ContentType | Journal Article |
Copyright | The Author(s) 2023 2023. Springer Nature Limited. The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Springer Nature Limited 2023 |
Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. Springer Nature Limited. – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Springer Nature Limited 2023 |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7X7 7XB 88E 8AO 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU COVID DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P5Z P62 P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 SOI 7X8 5PM ADTOC UNPAY DOA |
DOI | 10.1038/s41467-023-40960-0 |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biological Science Database Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts Environment Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Entomology Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Immunology Abstracts Environment Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 6 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2041-1723 |
EndPage | 11 |
ExternalDocumentID | oai_doaj_org_article_cee7a78f47b5458c87ac726e1a6998d6 10.1038/s41467-023-40960-0 PMC10449910 37620337 10_1038_s41467_023_40960_0 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) grantid: 1U19AI145825; R01AI120938; R01AI120938S1; R01AI128779 funderid: https://doi.org/10.13039/100000060 – fundername: U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) grantid: P30 CA 023108-41 funderid: https://doi.org/10.13039/100000054 – fundername: U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) grantid: P20-GM113132 funderid: https://doi.org/10.13039/100000057 – fundername: U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) grantid: K23HL151826 funderid: https://doi.org/10.13039/100000050 – fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) – fundername: NIAID NIH HHS grantid: HHSN272201400008C – fundername: NIGMS NIH HHS grantid: P20 GM113132 – fundername: NCI NIH HHS grantid: P30 CA023108 – fundername: NIAID NIH HHS grantid: R01 AI120938 – fundername: NIAID NIH HHS grantid: U19 AI145825 – fundername: NIAID NIH HHS grantid: R01 AI128779 – fundername: NHLBI NIH HHS grantid: K23 HL151826 – fundername: ; – fundername: ; grantid: P30 CA 023108-41 – fundername: ; grantid: P20-GM113132 – fundername: ; grantid: 1U19AI145825; R01AI120938; R01AI120938S1; R01AI128779 – fundername: ; grantid: K23HL151826 |
GroupedDBID | --- 0R~ 39C 3V. 53G 5VS 70F 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ AAHBH AAJSJ ABUWG ACGFO ACGFS ACIWK ACMJI ACPRK ACSMW ADBBV ADFRT ADMLS ADRAZ AENEX AEUYN AFKRA AFRAH AHMBA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH AOIJS ARAPS ASPBG AVWKF AZFZN BBNVY BCNDV BENPR BGLVJ BHPHI BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EE. EMOBN F5P FEDTE FYUFA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ KQ8 LGEZI LK8 LOTEE M1P M48 M7P M~E NADUK NAO NXXTH O9- OK1 P2P P62 PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT SV3 TSG UKHRP AASML AAYXX CITATION PHGZM PHGZT PJZUB PPXIY PQGLB PUEGO CGR CUY CVF ECM EIF NPM 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7XB 8FD 8FK AARCD AZQEC C1K COVID DWQXO FR3 GNUQQ H94 K9. P64 PKEHL PQEST PQUKI PRINS RC3 SOI 7X8 5PM 4.4 ADTOC BAPOH CAG COF EJD UNPAY |
ID | FETCH-LOGICAL-c541t-cf90ccdfa57a7a92dcb7640c71d1a316214c2ec4d97a3c327bc01f887c82c1b33 |
IEDL.DBID | UNPAY |
ISSN | 2041-1723 |
IngestDate | Wed Aug 27 01:33:00 EDT 2025 Wed Oct 01 16:53:37 EDT 2025 Tue Sep 30 17:11:48 EDT 2025 Fri Sep 05 03:29:08 EDT 2025 Wed Aug 13 04:10:15 EDT 2025 Mon Jul 21 05:43:26 EDT 2025 Wed Oct 01 02:52:31 EDT 2025 Thu Apr 24 22:51:37 EDT 2025 Fri Feb 21 02:39:59 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | 2023. Springer Nature Limited. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. cc-by |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c541t-cf90ccdfa57a7a92dcb7640c71d1a316214c2ec4d97a3c327bc01f887c82c1b33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-8809-1394 0000-0001-8181-9517 0000-0003-1054-0628 0000-0002-1340-4165 0000-0002-4253-3476 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://www.nature.com/articles/s41467-023-40960-0.pdf |
PMID | 37620337 |
PQID | 2856659885 |
PQPubID | 546298 |
PageCount | 11 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_cee7a78f47b5458c87ac726e1a6998d6 unpaywall_primary_10_1038_s41467_023_40960_0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10449910 proquest_miscellaneous_2857838556 proquest_journals_2856659885 pubmed_primary_37620337 crossref_citationtrail_10_1038_s41467_023_40960_0 crossref_primary_10_1038_s41467_023_40960_0 springer_journals_10_1038_s41467_023_40960_0 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-08-24 |
PublicationDateYYYYMMDD | 2023-08-24 |
PublicationDate_xml | – month: 08 year: 2023 text: 2023-08-24 day: 24 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Nature communications |
PublicationTitleAbbrev | Nat Commun |
PublicationTitleAlternate | Nat Commun |
PublicationYear | 2023 |
Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
References | Wang (CR14) 2022; 13 Tseng (CR62) 2022; 28 Gunn (CR32) 2021; 54 Dan (CR20) 2021; 371 Muik (CR53) 2022; 375 Butler (CR81) 2021; 11 Ellington (CR47) 2020; 69 Arunachalam (CR17) 2021; 596 Bowen (CR58) 2022; 7 Zhou (CR10) 2021; 184 Walls (CR56) 2020; 181 Wu (CR76) 2010; 329 Tarke (CR16) 2021; 2 Brown (CR74) 2012; 386 Om (CR68) 2020; 16 Richardson (CR26) 2022; 30 Amanat (CR15) 2021; 184 Tauzin (CR28) 2021; 29 Wang (CR9) 2021; 593 Chen (CR13) 2021; 27 Adeniji (CR25) 2021; 12 Polack (CR3) 2020; 383 CR49 Ackerman (CR65) 2018; 24 Miller-Novak (CR67) 2018; 92 Ullah (CR36) 2021; 54 Pajon (CR52) 2022; 386 Bégin (CR70) 2021; 27 Zohar (CR11) 2020; 183 Suryadevara (CR38) 2021; 184 Lee (CR60) 2022; 376 Anand (CR82) 2021; 2 Cui (CR40) 2022; 185 Hsieh (CR63) 2020; 369 Li, Sempowski, Saunders, Acharya, Haynes (CR37) 2022; 73 Atyeo (CR48) 2021; 13 Zohar (CR33) 2022; 30 Bates (CR43) 2021; 12 Feng (CR12) 2021; 27 Garcia-Beltran (CR29) 2021; 184 Baden (CR1) 2021; 384 Windsor (CR21) 2022; 7 Robbiani (CR46) 2020; 584 Boesch (CR73) 2014; 6 Fischinger (CR84) 2019; 473 Redd (CR23) 2021; 8 Wang (CR42) 2021; 595 Felber (CR66) 2020; 31 Rees-Spear (CR7) 2021; 34 CR55 Ackerman (CR80) 2011; 366 Wang (CR57) 2022; 13 Wang (CR6) 2021; 592 Pegu (CR4) 2021; 373 Dejnirattisai (CR41) 2022; 185 Tarke (CR19) 2022; 185 Long (CR44) 2020; 26 Dias (CR31) 2022; 14 Sievers (CR5) 2022; 14 Lucas (CR30) 2021; 600 Suscovich (CR69) 2020; 12 Chan (CR71) 2021; 16 Kaplonek (CR35) 2022; 55 Jackson (CR2) 2020; 383 Schmidt (CR8) 2022; 386 Kaplonek (CR54) 2022; 14 Yamin (CR72) 2021; 599 Winkler (CR27) 2021; 184 Chung (CR34) 2014; 6 Crowley (CR59) 2022; 11 Beaudoin-Bussières (CR24) 2022; 38 Reynolds (CR64) 2022; 377 Geers (CR18) 2021; 6 Brown (CR77) 2017; 443 Röltgen (CR45) 2020; 5 Redd (CR22) 2022; 13 Pinto (CR75) 2020; 583 Arien (CR79) 2022; 7 Beaudoin-Bussieres, Richard, Prevost, Goyette, Finzi (CR83) 2021; 2 Nimmerjahn, Ravetch (CR50) 2005; 310 Zauche (CR61) 2021; 385 Barnes (CR39) 2020; 182 Vidarsson, Dekkers, Rispens (CR51) 2014; 5 Brown (CR78) 2018; 455 LR Baden (40960_CR1) 2021; 384 A Pegu (40960_CR4) 2021; 373 F Amanat (40960_CR15) 2021; 184 JM Dan (40960_CR20) 2021; 371 BM Gunn (40960_CR32) 2021; 54 CO Barnes (40960_CR39) 2020; 182 40960_CR49 C Wang (40960_CR57) 2022; 13 OS Adeniji (40960_CR25) 2021; 12 S Fischinger (40960_CR84) 2019; 473 D Geers (40960_CR18) 2021; 6 P Kaplonek (40960_CR35) 2022; 55 ME Ackerman (40960_CR80) 2011; 366 P Kaplonek (40960_CR54) 2022; 14 F Schmidt (40960_CR8) 2022; 386 C Rees-Spear (40960_CR7) 2021; 34 LH Zauche (40960_CR61) 2021; 385 EP Brown (40960_CR77) 2017; 443 K Röltgen (40960_CR45) 2020; 5 LA Jackson (40960_CR2) 2020; 383 AR Crowley (40960_CR59) 2022; 11 R Yamin (40960_CR72) 2021; 599 I Ullah (40960_CR36) 2021; 54 WF Garcia-Beltran (40960_CR29) 2021; 184 G Vidarsson (40960_CR51) 2014; 5 CEZ Chan (40960_CR71) 2021; 16 A Tarke (40960_CR16) 2021; 2 W Dejnirattisai (40960_CR41) 2022; 185 SI Richardson (40960_CR26) 2022; 30 T Zohar (40960_CR33) 2022; 30 A Muik (40960_CR53) 2022; 375 P Bégin (40960_CR70) 2021; 27 Z Wang (40960_CR42) 2021; 595 Z Wang (40960_CR6) 2021; 592 PS Arunachalam (40960_CR17) 2021; 596 TA Bates (40960_CR43) 2021; 12 S Ellington (40960_CR47) 2020; 69 N Suryadevara (40960_CR38) 2021; 184 A Tauzin (40960_CR28) 2021; 29 EP Brown (40960_CR74) 2012; 386 G Beaudoin-Bussieres (40960_CR83) 2021; 2 AD Redd (40960_CR23) 2021; 8 LK Miller-Novak (40960_CR67) 2018; 92 TJ Suscovich (40960_CR69) 2020; 12 Z Cui (40960_CR40) 2022; 185 F Nimmerjahn (40960_CR50) 2005; 310 AD Redd (40960_CR22) 2022; 13 L Wang (40960_CR14) 2022; 13 BL Sievers (40960_CR5) 2022; 14 S Feng (40960_CR12) 2021; 27 A Tarke (40960_CR19) 2022; 185 BK Felber (40960_CR66) 2020; 31 D Pinto (40960_CR75) 2020; 583 K Om (40960_CR68) 2020; 16 AW Boesch (40960_CR73) 2014; 6 RE Chen (40960_CR13) 2021; 27 D Li (40960_CR37) 2022; 73 SE Butler (40960_CR81) 2021; 11 KK Arien (40960_CR79) 2022; 7 C Atyeo (40960_CR48) 2021; 13 AW Chung (40960_CR34) 2014; 6 R Pajon (40960_CR52) 2022; 386 ARYB Lee (40960_CR60) 2022; 376 EP Brown (40960_CR78) 2018; 455 HF Tseng (40960_CR62) 2022; 28 G Beaudoin-Bussières (40960_CR24) 2022; 38 T Zohar (40960_CR11) 2020; 183 IW Windsor (40960_CR21) 2022; 7 40960_CR55 CL Hsieh (40960_CR63) 2020; 369 X Wu (40960_CR76) 2010; 329 SP Anand (40960_CR82) 2021; 2 AC Walls (40960_CR56) 2020; 181 DF Robbiani (40960_CR46) 2020; 584 D Zhou (40960_CR10) 2021; 184 Q-X Long (40960_CR44) 2020; 26 AG Dias Jr (40960_CR31) 2022; 14 JE Bowen (40960_CR58) 2022; 7 FP Polack (40960_CR3) 2020; 383 CJ Reynolds (40960_CR64) 2022; 377 P Wang (40960_CR9) 2021; 593 ES Winkler (40960_CR27) 2021; 184 C Lucas (40960_CR30) 2021; 600 ME Ackerman (40960_CR65) 2018; 24 36172122 - medRxiv. 2022 Sep 18:2022.09.15.22280000. doi: 10.1101/2022.09.15.22280000 |
References_xml | – volume: 6 start-page: 228ra238 year: 2014 ident: CR34 article-title: Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 Vaccines publication-title: Sci. Transl. Med. – volume: 181 start-page: 281 year: 2020 end-page: 292.e286 ident: CR56 article-title: Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein publication-title: Cell – volume: 184 start-page: 2316 year: 2021 end-page: 2331.e2315 ident: CR38 article-title: Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein publication-title: Cell – volume: 386 start-page: 117 year: 2012 end-page: 123 ident: CR74 article-title: High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples publication-title: J. Immunol. Methods – ident: CR49 – volume: 6 start-page: eabj1750 year: 2021 ident: CR18 article-title: SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees publication-title: Sci. Immunol. – volume: 31 start-page: 107624 year: 2020 ident: CR66 article-title: Co-immunization of DNA and protein in the same anatomical sites induces superior protective immune responses against SHIV challenge publication-title: Cell Rep. – volume: 596 start-page: 410 year: 2021 end-page: 416 ident: CR17 article-title: Systems vaccinology of the BNT162b2 mRNA vaccine in humans publication-title: Nature – volume: 329 start-page: 856 year: 2010 end-page: 861 ident: CR76 article-title: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 publication-title: Science – volume: 14 start-page: eabm3151 year: 2022 ident: CR31 article-title: Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection publication-title: Sci. Transl. Med. – volume: 383 start-page: 2603 year: 2020 end-page: 2615 ident: CR3 article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine publication-title: N. Engl. J. Med. – volume: 12 start-page: eabb4757 year: 2020 ident: CR69 article-title: Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination publication-title: Sci. Transl. Med. – volume: 183 start-page: 1508 year: 2020 end-page: 1519.e1512 ident: CR11 article-title: Compromised humoral functional evolution tracks with SARS-CoV-2 mortality publication-title: Cell – volume: 366 start-page: 8 year: 2011 end-page: 19 ident: CR80 article-title: A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples publication-title: J. Immunol. Methods – volume: 2 start-page: 100290 year: 2021 ident: CR82 article-title: Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset publication-title: Cell Rep. Med. – volume: 185 start-page: 860 year: 2022 end-page: 871.e813 ident: CR40 article-title: Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron publication-title: Cell – volume: 16 start-page: e0253487 year: 2021 ident: CR71 article-title: The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody publication-title: PLoS ONE – volume: 377 start-page: eabq1841 year: 2022 ident: CR64 article-title: Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure publication-title: Science – volume: 34 start-page: 108890 year: 2021 ident: CR7 article-title: The effect of spike mutations on SARS-CoV-2 neutralization publication-title: Cell Rep. – volume: 184 start-page: 2372 year: 2021 end-page: 2383.e2379 ident: CR29 article-title: Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity publication-title: Cell – volume: 11 start-page: e75228 year: 2022 ident: CR59 article-title: Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike publication-title: Elife – volume: 595 start-page: 426 year: 2021 end-page: 431 ident: CR42 article-title: Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection publication-title: Nature – volume: 29 start-page: 1137 year: 2021 end-page: 1150.e1136 ident: CR28 article-title: A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses publication-title: Cell Host Microbe – volume: 12 start-page: e00281 year: 2021 end-page: 21 ident: CR25 article-title: COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions publication-title: mBio – volume: 584 start-page: 437 year: 2020 end-page: 442 ident: CR46 article-title: Convergent antibody responses to SARS-CoV-2 in convalescent individuals publication-title: Nature – volume: 12 year: 2021 ident: CR43 article-title: Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum publication-title: Nat. Commun. – volume: 27 start-page: 717 year: 2021 end-page: 726 ident: CR13 article-title: Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies publication-title: Nat. Med. – volume: 24 start-page: 1590 year: 2018 end-page: 1598 ident: CR65 article-title: Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV publication-title: Nat. Med. – volume: 69 start-page: 769 year: 2020 end-page: 775 ident: CR47 article-title: Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22-June 7, 2020 publication-title: MMWR Morb. Mortal. Wkly Rep. – volume: 13 year: 2022 ident: CR57 article-title: Antigenic structure of the human coronavirus OC43 spike reveals exposed and occluded neutralizing epitopes publication-title: Nat. Commun. – volume: 28 start-page: 1063 year: 2022 end-page: 1071 ident: CR62 article-title: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants publication-title: Nat. Med. – volume: 185 start-page: 847 year: 2022 end-page: 859.e811 ident: CR19 article-title: SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron publication-title: Cell – volume: 182 start-page: 828 year: 2020 end-page: 842.e816 ident: CR39 article-title: Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies publication-title: Cell – volume: 11 start-page: 618685 year: 2021 ident: CR81 article-title: Distinct features and functions of systemic and mucosal humoral immunity among SARS-CoV-2 convalescent individuals publication-title: Front. Immunol. – volume: 13 start-page: e0361721 year: 2022 ident: CR22 article-title: Minimal crossover between mutations associated with omicron variant of SARS-CoV-2 and CD8(+) T-cell epitopes identified in COVID-19 convalescent individuals publication-title: mBio – volume: 6 start-page: 915 year: 2014 end-page: 927 ident: CR73 article-title: Highly parallel characterization of IgG Fc binding interactions publication-title: MAbs – volume: 14 start-page: eabm2311 year: 2022 ident: CR54 article-title: mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions publication-title: Sci. Transl. Med. – volume: 369 start-page: 1501 year: 2020 end-page: 1505 ident: CR63 article-title: Structure-based design of prefusion-stabilized SARS-CoV-2 spikes publication-title: Science – volume: 7 start-page: eabo3425 year: 2022 ident: CR21 article-title: Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1 publication-title: Sci. Immunol. – volume: 13 start-page: eabi8631 year: 2021 ident: CR48 article-title: COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women publication-title: Sci. Transl. Med. – volume: 600 start-page: 523 year: 2021 end-page: 529 ident: CR30 article-title: Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity publication-title: Nature – volume: 385 start-page: 1533 year: 2021 end-page: 1535 ident: CR61 article-title: Receipt of mRNA Covid-19 vaccines and risk of spontaneous abortion publication-title: N. Engl. J. Med. – volume: 373 start-page: 1372 year: 2021 end-page: 1377 ident: CR4 article-title: Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants publication-title: Science – volume: 73 start-page: 1 year: 2022 end-page: 16 ident: CR37 article-title: SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment publication-title: Annu. Rev. Med. – volume: 583 start-page: 290 year: 2020 end-page: 295 ident: CR75 article-title: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody publication-title: Nature – volume: 5 start-page: 520 year: 2014 ident: CR51 article-title: IgG subclasses and allotypes: from structure to effector functions publication-title: Front. Immunol. – volume: 371 start-page: eabf4063 year: 2021 ident: CR20 article-title: Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection publication-title: Science – volume: 5 start-page: eabe0240 year: 2020 ident: CR45 article-title: Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome publication-title: Sci. Immunol. – volume: 2 start-page: 100355 year: 2021 ident: CR16 article-title: Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals publication-title: Cell Rep. Med. – volume: 184 start-page: 1804 year: 2021 end-page: 1820.e1816 ident: CR27 article-title: Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection publication-title: Cell – volume: 599 start-page: 465 year: 2021 end-page: 470 ident: CR72 article-title: Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy publication-title: Nature – volume: 593 start-page: 130 year: 2021 end-page: 135 ident: CR9 article-title: Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 publication-title: Nature – volume: 592 start-page: 616 year: 2021 end-page: 622 ident: CR6 article-title: mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants publication-title: Nature – volume: 310 start-page: 1510 year: 2005 end-page: 1512 ident: CR50 article-title: Divergent immunoglobulin g subclass activity through selective Fc receptor binding publication-title: Science – volume: 384 start-page: 403 year: 2021 end-page: 416 ident: CR1 article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine publication-title: N. Engl. J. Med. – volume: 2 start-page: 100851 year: 2021 ident: CR83 article-title: A new flow cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-expressing cells publication-title: STAR Protoc. – volume: 7 year: 2022 ident: CR79 article-title: Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant publication-title: NPJ Vaccines – volume: 30 start-page: 41 year: 2022 end-page: 52.e45 ident: CR33 article-title: Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates publication-title: Cell Host Microbe – volume: 473 start-page: 112630 year: 2019 ident: CR84 article-title: A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation publication-title: J. Immunol. Methods – volume: 383 start-page: 1920 year: 2020 end-page: 1931 ident: CR2 article-title: An mRNA vaccine against SARS-CoV-2—preliminary report publication-title: N. Engl. J. Med. – volume: 55 start-page: 355 year: 2022 end-page: 365.e354 ident: CR35 article-title: mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern publication-title: Immunity – volume: 375 start-page: 678 year: 2022 end-page: 680 ident: CR53 article-title: Neutralization of SARS-CoV-2 omicron by BNT162b2 mRNA vaccine-elicited human sera publication-title: Science – volume: 92 start-page: e00721 year: 2018 end-page: 18 ident: CR67 article-title: Analysis of complement-mediated lysis of simian immunodeficiency virus (SIV) and SIV-infected cells reveals sex differences in vaccine-induced immune responses in publication-title: J. Virol. – volume: 26 start-page: 845 year: 2020 end-page: 848 ident: CR44 article-title: Antibody responses to SARS-CoV-2 in patients with COVID-19 publication-title: Nat. Med. – volume: 38 start-page: 110368 year: 2022 ident: CR24 article-title: A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection publication-title: Cell Rep. – volume: 184 start-page: 2348 year: 2021 end-page: 2361.e2346 ident: CR10 article-title: Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera publication-title: Cell – volume: 27 start-page: 2032 year: 2021 end-page: 2040 ident: CR12 article-title: Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection publication-title: Nat. Med. – volume: 54 start-page: 2143 year: 2021 end-page: 2158.e2115 ident: CR36 article-title: Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy publication-title: Immunity – volume: 16 start-page: e1008764 year: 2020 ident: CR68 article-title: Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge publication-title: PLoS Pathog. – volume: 14 start-page: eabn7842 year: 2022 ident: CR5 article-title: Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses publication-title: Sci. Transl. Med. – volume: 386 start-page: 599 year: 2022 end-page: 601 ident: CR8 article-title: Plasma neutralization of the SARS-CoV-2 omicron variant publication-title: N. Engl. J. Med. – volume: 30 start-page: 880 year: 2022 end-page: 886.e884 ident: CR26 article-title: SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals publication-title: Cell Host Microbe – volume: 455 start-page: 24 year: 2018 end-page: 33 ident: CR78 article-title: Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV publication-title: J. Immunol. Methods – volume: 443 start-page: 33 year: 2017 end-page: 44 ident: CR77 article-title: Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles publication-title: J. Immunol. Methods – volume: 27 start-page: 2012 year: 2021 end-page: 2024 ident: CR70 article-title: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial publication-title: Nat. Med. – volume: 184 start-page: 3936 year: 2021 end-page: 3948.e3910 ident: CR15 article-title: SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 publication-title: Cell – volume: 13 year: 2022 ident: CR14 article-title: Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines publication-title: Nat. Commun. – volume: 8 start-page: ofab143 year: 2021 ident: CR23 article-title: CD8+ T-cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants publication-title: Open Forum Infect. Dis. – volume: 7 start-page: eadf1421 year: 2022 ident: CR58 article-title: SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines publication-title: Sci. Immunol. – ident: CR55 – volume: 376 start-page: e068632 year: 2022 ident: CR60 article-title: Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis publication-title: BMJ – volume: 54 start-page: 815 year: 2021 end-page: 828.e815 ident: CR32 article-title: A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus publication-title: Immunity – volume: 185 start-page: 467 year: 2022 end-page: 484.e415 ident: CR41 article-title: SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses publication-title: Cell – volume: 386 start-page: 1088 year: 2022 end-page: 1091 ident: CR52 article-title: SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination publication-title: N. Engl. J. Med. – volume: 13 year: 2022 ident: 40960_CR14 publication-title: Nat. Commun. – volume: 185 start-page: 467 year: 2022 ident: 40960_CR41 publication-title: Cell doi: 10.1016/j.cell.2021.12.046 – volume: 592 start-page: 616 year: 2021 ident: 40960_CR6 publication-title: Nature doi: 10.1038/s41586-021-03324-6 – volume: 184 start-page: 3936 year: 2021 ident: 40960_CR15 publication-title: Cell doi: 10.1016/j.cell.2021.06.005 – volume: 583 start-page: 290 year: 2020 ident: 40960_CR75 publication-title: Nature doi: 10.1038/s41586-020-2349-y – volume: 383 start-page: 2603 year: 2020 ident: 40960_CR3 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2034577 – volume: 5 start-page: 520 year: 2014 ident: 40960_CR51 publication-title: Front. Immunol. doi: 10.3389/fimmu.2014.00520 – volume: 366 start-page: 8 year: 2011 ident: 40960_CR80 publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2010.12.016 – volume: 54 start-page: 2143 year: 2021 ident: 40960_CR36 publication-title: Immunity doi: 10.1016/j.immuni.2021.08.015 – volume: 34 start-page: 108890 year: 2021 ident: 40960_CR7 publication-title: Cell Rep. doi: 10.1016/j.celrep.2021.108890 – volume: 184 start-page: 2348 year: 2021 ident: 40960_CR10 publication-title: Cell doi: 10.1016/j.cell.2021.02.037 – volume: 13 start-page: e0361721 year: 2022 ident: 40960_CR22 publication-title: mBio doi: 10.1128/mbio.03617-21 – volume: 386 start-page: 117 year: 2012 ident: 40960_CR74 publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2012.09.007 – volume: 373 start-page: 1372 year: 2021 ident: 40960_CR4 publication-title: Science doi: 10.1126/science.abj4176 – volume: 73 start-page: 1 year: 2022 ident: 40960_CR37 publication-title: Annu. Rev. Med. doi: 10.1146/annurev-med-042420-113838 – volume: 185 start-page: 860 year: 2022 ident: 40960_CR40 publication-title: Cell doi: 10.1016/j.cell.2022.01.019 – volume: 27 start-page: 2032 year: 2021 ident: 40960_CR12 publication-title: Nat. Med. doi: 10.1038/s41591-021-01540-1 – volume: 8 start-page: ofab143 year: 2021 ident: 40960_CR23 publication-title: Open Forum Infect. Dis. doi: 10.1093/ofid/ofab143 – volume: 184 start-page: 1804 year: 2021 ident: 40960_CR27 publication-title: Cell doi: 10.1016/j.cell.2021.02.026 – volume: 181 start-page: 281 year: 2020 ident: 40960_CR56 publication-title: Cell doi: 10.1016/j.cell.2020.02.058 – volume: 443 start-page: 33 year: 2017 ident: 40960_CR77 publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2017.01.010 – volume: 329 start-page: 856 year: 2010 ident: 40960_CR76 publication-title: Science doi: 10.1126/science.1187659 – volume: 184 start-page: 2372 year: 2021 ident: 40960_CR29 publication-title: Cell doi: 10.1016/j.cell.2021.03.013 – volume: 383 start-page: 1920 year: 2020 ident: 40960_CR2 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2022483 – volume: 596 start-page: 410 year: 2021 ident: 40960_CR17 publication-title: Nature doi: 10.1038/s41586-021-03791-x – volume: 16 start-page: e1008764 year: 2020 ident: 40960_CR68 publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1008764 – volume: 185 start-page: 847 year: 2022 ident: 40960_CR19 publication-title: Cell doi: 10.1016/j.cell.2022.01.015 – volume: 13 year: 2022 ident: 40960_CR57 publication-title: Nat. Commun. – volume: 13 start-page: eabi8631 year: 2021 ident: 40960_CR48 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abi8631 – volume: 599 start-page: 465 year: 2021 ident: 40960_CR72 publication-title: Nature doi: 10.1038/s41586-021-04017-w – volume: 12 start-page: e00281 year: 2021 ident: 40960_CR25 publication-title: mBio – volume: 310 start-page: 1510 year: 2005 ident: 40960_CR50 publication-title: Science doi: 10.1126/science.1118948 – volume: 384 start-page: 403 year: 2021 ident: 40960_CR1 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2035389 – volume: 30 start-page: 41 year: 2022 ident: 40960_CR33 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2021.11.006 – volume: 14 start-page: eabm3151 year: 2022 ident: 40960_CR31 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abm3151 – volume: 12 year: 2021 ident: 40960_CR43 publication-title: Nat. Commun. – volume: 385 start-page: 1533 year: 2021 ident: 40960_CR61 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2113891 – volume: 386 start-page: 1088 year: 2022 ident: 40960_CR52 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2119912 – volume: 593 start-page: 130 year: 2021 ident: 40960_CR9 publication-title: Nature doi: 10.1038/s41586-021-03398-2 – volume: 6 start-page: 915 year: 2014 ident: 40960_CR73 publication-title: MAbs doi: 10.4161/mabs.28808 – volume: 7 year: 2022 ident: 40960_CR79 publication-title: NPJ Vaccines doi: 10.1038/s41541-022-00459-z – volume: 55 start-page: 355 year: 2022 ident: 40960_CR35 publication-title: Immunity doi: 10.1016/j.immuni.2022.01.001 – volume: 27 start-page: 717 year: 2021 ident: 40960_CR13 publication-title: Nat. Med. doi: 10.1038/s41591-021-01294-w – volume: 183 start-page: 1508 year: 2020 ident: 40960_CR11 publication-title: Cell doi: 10.1016/j.cell.2020.10.052 – volume: 26 start-page: 845 year: 2020 ident: 40960_CR44 publication-title: Nat. Med. doi: 10.1038/s41591-020-0897-1 – volume: 2 start-page: 100290 year: 2021 ident: 40960_CR82 publication-title: Cell Rep. Med. doi: 10.1016/j.xcrm.2021.100290 – volume: 600 start-page: 523 year: 2021 ident: 40960_CR30 publication-title: Nature doi: 10.1038/s41586-021-04085-y – volume: 6 start-page: eabj1750 year: 2021 ident: 40960_CR18 publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.abj1750 – volume: 31 start-page: 107624 year: 2020 ident: 40960_CR66 publication-title: Cell Rep. doi: 10.1016/j.celrep.2020.107624 – volume: 28 start-page: 1063 year: 2022 ident: 40960_CR62 publication-title: Nat. Med. doi: 10.1038/s41591-022-01753-y – ident: 40960_CR55 doi: 10.3389/fmed.2021.628370 – volume: 11 start-page: 618685 year: 2021 ident: 40960_CR81 publication-title: Front. Immunol. doi: 10.3389/fimmu.2020.618685 – volume: 24 start-page: 1590 year: 2018 ident: 40960_CR65 publication-title: Nat. Med. doi: 10.1038/s41591-018-0161-0 – volume: 6 start-page: 228ra238 year: 2014 ident: 40960_CR34 publication-title: Sci. Transl. Med. – volume: 455 start-page: 24 year: 2018 ident: 40960_CR78 publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2018.01.013 – volume: 595 start-page: 426 year: 2021 ident: 40960_CR42 publication-title: Nature doi: 10.1038/s41586-021-03696-9 – volume: 386 start-page: 599 year: 2022 ident: 40960_CR8 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2119641 – volume: 184 start-page: 2316 year: 2021 ident: 40960_CR38 publication-title: Cell doi: 10.1016/j.cell.2021.03.029 – volume: 2 start-page: 100355 year: 2021 ident: 40960_CR16 publication-title: Cell Rep. Med. doi: 10.1016/j.xcrm.2021.100355 – volume: 16 start-page: e0253487 year: 2021 ident: 40960_CR71 publication-title: PLoS ONE doi: 10.1371/journal.pone.0253487 – volume: 54 start-page: 815 year: 2021 ident: 40960_CR32 publication-title: Immunity doi: 10.1016/j.immuni.2021.03.009 – ident: 40960_CR49 doi: 10.48550/arXiv.1802.03426 – volume: 7 start-page: eabo3425 year: 2022 ident: 40960_CR21 publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.abo3425 – volume: 5 start-page: eabe0240 year: 2020 ident: 40960_CR45 publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.abe0240 – volume: 7 start-page: eadf1421 year: 2022 ident: 40960_CR58 publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.adf1421 – volume: 473 start-page: 112630 year: 2019 ident: 40960_CR84 publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2019.07.002 – volume: 12 start-page: eabb4757 year: 2020 ident: 40960_CR69 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abb4757 – volume: 27 start-page: 2012 year: 2021 ident: 40960_CR70 publication-title: Nat. Med. doi: 10.1038/s41591-021-01488-2 – volume: 376 start-page: e068632 year: 2022 ident: 40960_CR60 publication-title: BMJ – volume: 92 start-page: e00721 year: 2018 ident: 40960_CR67 publication-title: J. Virol. – volume: 584 start-page: 437 year: 2020 ident: 40960_CR46 publication-title: Nature doi: 10.1038/s41586-020-2456-9 – volume: 2 start-page: 100851 year: 2021 ident: 40960_CR83 publication-title: STAR Protoc. doi: 10.1016/j.xpro.2021.100851 – volume: 371 start-page: eabf4063 year: 2021 ident: 40960_CR20 publication-title: Science doi: 10.1126/science.abf4063 – volume: 377 start-page: eabq1841 year: 2022 ident: 40960_CR64 publication-title: Science doi: 10.1126/science.abq1841 – volume: 30 start-page: 880 year: 2022 ident: 40960_CR26 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2022.03.029 – volume: 11 start-page: e75228 year: 2022 ident: 40960_CR59 publication-title: Elife doi: 10.7554/eLife.75228 – volume: 29 start-page: 1137 year: 2021 ident: 40960_CR28 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2021.06.001 – volume: 14 start-page: eabn7842 year: 2022 ident: 40960_CR5 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abn7842 – volume: 375 start-page: 678 year: 2022 ident: 40960_CR53 publication-title: Science doi: 10.1126/science.abn7591 – volume: 369 start-page: 1501 year: 2020 ident: 40960_CR63 publication-title: Science doi: 10.1126/science.abd0826 – volume: 38 start-page: 110368 year: 2022 ident: 40960_CR24 publication-title: Cell Rep. doi: 10.1016/j.celrep.2022.110368 – volume: 182 start-page: 828 year: 2020 ident: 40960_CR39 publication-title: Cell doi: 10.1016/j.cell.2020.06.025 – volume: 69 start-page: 769 year: 2020 ident: 40960_CR47 publication-title: MMWR Morb. Mortal. Wkly Rep. doi: 10.15585/mmwr.mm6925a1 – volume: 14 start-page: eabm2311 year: 2022 ident: 40960_CR54 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abm2311 – reference: 36172122 - medRxiv. 2022 Sep 18:2022.09.15.22280000. doi: 10.1101/2022.09.15.22280000 |
SSID | ssj0000391844 |
Score | 2.4476972 |
Snippet | SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other... Abstract SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to... |
SourceID | doaj unpaywall pubmedcentral proquest pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 5171 |
SubjectTerms | 13/106 13/109 13/31 49/1 49/31 49/79 631/250/2152/2153/1291 631/250/255/2514 82/1 Antibodies Antibody response At risk populations Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 Vaccines Female Humanities and Social Sciences Humans mRNA multidisciplinary Neutralization Pandemics Populations Pregnancy Pregnancy Complications, Infectious Recognition SARS-CoV-2 Science Science (multidisciplinary) Severe acute respiratory syndrome coronavirus 2 Vaccination Vaccines Viral diseases Vulnerable Populations |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9RAFB6kIOqDeO_WKiP4ZkMzt8zksRZLEfTBWulbmDmTYCAky262stAf75lJNu6iVB98C5kLM2e-c5vLOYS89XmVWW1V4vOSJ1LmPEEzxCFfSe8YaF1VYb_j0-fs_FJ-vFJXW6m-wp2wITzwQLhjFOLaalNJ7cIZDxhtQfOsZDZDT8HHYNuoxracqSiDRY6uixxfyaTCHC9llAmootBlQrM9SXc0UQzY_ycr8_fLktOJ6QNyb9XO7fqHbZotpXT2iDwcrUl6MsziMblTtk_I3SG_5Popubk4-XKRnHbfEk6vLUA9bP3Rsqmh7pfULTrrqW09nXdoO_f42deu82s6XPPoFjTovQhN2nfYB8K1xYZdRSG8d1y0tG7p9aoJsatdU2I_m3xgy2fk8uzD19PzZEy3kICSrE-gylMAX1mFBLc59-B0JlPQzDMrWMaZBF6C9Lm2AgTXDlJWoZACw4E5IZ6TvbZry31CK1tWSvnUCy-l0D632MwZz3xqPQg7I2xD-gLGWOQhJUZTxDNxYYphuQpcriIuV5HOyLupzXyIxHFr7fdhRaeaIYp2_IHYKkZsFX_D1owcbvBQjKy9LLhBC1jlxqgZeTMVI1OGkxbblt0q1tFGGKWwixcDfKaRoETnqRB6RswOsHaGulvS1t9j4G90ndFBZTi5ow0Gf43rNlocTTj9B9Id_A_SvST3eeC1FOWwPCR7_WJVvkLzrXevI6f-BHm1QWw priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA96IuqD-O3qKRF888o1H23SJzkP10PQB8-TeyvJpD0LpVm33ZMF_3gnbbfnoiy-leaDJPObyWQmmSHktcvK1CiTRC4reCRlxiNUQyzylXSWgVJlGewdnz6nJ2fy43lyPhrc2vFa5UYm9oLaeQg28kOuUfFIMq2Tt4sfUcgaFbyrYwqN6-QG44ik8FJ8_mGysYTo51rK8a1MLPRhK3vJgBsVHpxQeY_irf2oD9v_L13z7yuTk9_0Drm1ahZm_dPU9R9b0_weuTvqlPRoAMF9cq1oHpCbQ5bJ9UPy6_Toy2l07L9FnF4agGowANKirqDqWmqX3jhqGkcXHjXoDj-7ynq3psNlD7-kYffrAUo7j30gaBts6EsK4dXjsqFVQy9XdYhgbesC-9lkBWsfkbP5-6_HJ9GYdCGCRLIugjKLAVxpEoU0zLgDq1IZg2KOGcFSziTwAqTLlBEguLIQsxJFFWgOzArxmOw1vimeElqaokwSFzvhpBTKZQabWe2Yi40DYWaEbZY-hzEieUiMUee9Z1zofCBXjuTKe3Ll8Yy8mdoshngcO2u_CxSdaoZY2v0Pv7zIR9bMUU3AqepSKhu8iKCVAcXTgpkUz6IunZH9DR7ykcHb_AqOM_JqKkbWDP4W0xR-1ddRWugkwS6eDPCZRoJyncdCqBnRW8DaGup2SVN978N_4wEaj6kMJ3ewweDVuHatxcGE0_9Yume7Z_2c3OaBi2KUs3Kf7HXLVfEC1bPOvux58DefiTi3 priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA_niagP4rerp0QQX7xq89EmfRA5D49DOB88V-6tJJNWC6Xd63ZPF_zjnfRLF5fDt9J8kGR-k5nJJDOEvHBJHhtlosAlGQ-kTHiAaohFvpLOMlAqz_15x8mn-HguP55FZztkvG47LOByq2nn80nNm_L1z_P1O2T4t_2Tcf1mKTt2R-mD1hBq5EH4cnEe-MRS3gE7ZNm4Qq6isOIe-CeDBdBt1iJBG0cOz2m297YhsrrI_tvU0X9vVU6u1Zvk-qpamPUPU5Z_Sa-j2-TWoHbSgx4nd8hOVt0l1_pElOt75NfpwefT4LD-GnB6YQCK_oyQZmUBRbuktqmNo6ZydFGjkt3iZ1vY2q1pfx-kbqgXkB2GaVtjH4jrChvWOQX_MLKpaFHRi1Xpg1zbMsN-xsRhy_tkfvThy-FxMORlCCCSrA0gT0IAl5tIIZkT7sCqWIagmGNGsJgzCTwD6RJlBAiuLIQsx90MNAdmhXhAdqu6yh4RmpssjyIXOuGkFMolBptZ7ZgLjQNhZoSNS5_CELTc584o0855LnTakytFcqUdudJwRl5NbRZ9yI5La7_3FJ1q-nDb3Y-6-ZYO3JuiJoFT1blU1jsaQSsDiscZMzGaqy6ekb0RD-kI4ZRrVJWjROtoRp5Pxci93iVjqqxedXWUFjqKsIuHPXymkeDWz0Mh1IzoDWBtDHWzpCq-dxHC0cZGS5bh5PZHDP4Z12VrsT_h9D-W7vHls35CbnDPRSFuxXKP7LbNKnuKGlxrn3U8-BtlT0NZ priority: 102 providerName: Scholars Portal – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA_HiagP4rfVUyL45hWbjzbp47l4HII-eJ7cW0kmrRZKu-x271i4P95J-qGLx6FvpcmEJPObZCYzmRDy1uVVZpRJY5eXPJYy5zGqIRblSjrLQKmq8ucdn79kJ2fy03l6vkf4dBcmBO2HlJZhmZ6iw96vZRBp3GHQ4kGtO0Yz_ZZWgvkwvkW2mM9VfMZzLeV4PyYR-hrSnT0opOq_Tr_8O0xy9pXeI3c27dJsL03T_LEdHT8g90c9kh4NPX9I9sr2Ebk9vCy5fUyuTo--nsaL7nvM6YUBqIdDP1o2NdT9mtpVZxw1raPLDrXmHj_72nZuS4cAj25F_Y4XQEn7DttAoLZI2FUU_E3HVUvrll5sGp-12jYltjO9BLZ-Qs6OP35bnMTjQwsxpJL1MVR5AuAqkyrkW84dWJXJBBRzzAiWcSaBlyBdrowAwZWFhFW4PIHmwKwQT8l-27Xlc0IrU1Zp6hInnJRCudwgmdWOucQ4ECYibJr6AsYs5P4xjKYI3nChi4FdBbKrCOwqkoi8m2mWQw6OG2t_8Byda_r82eFHt_pRjHgqUDXAoepKKus9h6CVAcWzkpkM7U-XReRgwkMxCvW64Bp13zTXOo3Im7kYxdH7WExbdptQR2mh0xSbeDbAZ-4JruU8EUJFRO8Aa6eruyVt_TOk_EajGU1ThoM7nDD4u183zcXhjNN_mLoX_9f6S3KXe6lKcK2VB2S_X23KV6ii9fZ1kMlfLjg2TA priority: 102 providerName: Springer Nature |
Title | SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations |
URI | https://link.springer.com/article/10.1038/s41467-023-40960-0 https://www.ncbi.nlm.nih.gov/pubmed/37620337 https://www.proquest.com/docview/2856659885 https://www.proquest.com/docview/2857838556 https://pubmed.ncbi.nlm.nih.gov/PMC10449910 https://www.nature.com/articles/s41467-023-40960-0.pdf https://doaj.org/article/cee7a78f47b5458c87ac726e1a6998d6 |
UnpaywallVersion | publishedVersion |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: KQ8 dateStart: 20150101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Open Access Full Text customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: DOA dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: Inspec with Full Text customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: ADMLS dateStart: 20121101 isFulltext: true titleUrlDefault: https://www.ebsco.com/products/research-databases/inspec-full-text providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: DIK dateStart: 20100101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: RPM dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVAQT databaseName: Springer Nature - nature.com Journals - Fully Open Access customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: NAO dateStart: 20101201 isFulltext: true titleUrlDefault: https://www.nature.com/siteindex/index.html providerName: Nature Publishing – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: 7X7 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central (ProQuest) customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2041-1723 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: BENPR dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Technology Collection customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: 8FG dateStart: 20100401 isFulltext: true titleUrlDefault: https://search.proquest.com/technologycollection1 providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2041-1723 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: M48 dateStart: 20101001 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: Springer Nature HAS Fully OA customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: AAJSJ dateStart: 20101201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: C6C dateStart: 20101201 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1rb9Mw0NpaIeAD70dhVEbiG0uJH4mdj121MlVaNa0UxqfIsROIiJKqTYeK-PGc8ygUpol9SaLkbNmXe9l3vkPojQkSXwnlOSaIqcN5QB0wQyLgK24iooVIErvfcTr1T-Z8cuFd7CG_PQtTBe1XKS0rMd1Gh71b8YqlQcPAigesbscdLEyyj7q-dSx1UHc-PRt-tpXkXE4c0MqsOSHjMnlF4x0tVCXrv8rC_DdQcustvYtur_OF2nxXWfaHQhrfR5_aqdRxKN8G6zIa6B9_ZXm8-VwfoHuNjYqHNeRDtBfnj9Ctumrl5jH6ORuez5xR8dGh-FJpndYbijjOUp2WKxwtC2Wwyg1eFGCRl_BYplFhNrgOHimW2GrTiuBxWUAfwAQ5NCwSrO0pymWO0xxfrjObETvKYuinrTK2eoLm4-MPoxOnKeLgaI-T0tFJ4GptEuUJoImAGh0Jn7taEEMUIz4lXNNYcxMIxTSjItIuSUD0aUk1iRh7ijp5kcfPEU5UnHiecQ0znDNhAgXNImmIcZXRTPUQaX9qqJsM57bQRhZWnnYmwxqzIWA2rDAbuj30dttmUef3uBb6yNLKFtLm5q5eFMsvYfP_QjA7YKoy4SKyXkkthdKC-jFRPqxtjd9DBy2lhY3AWIVUgl3tBVJ6PfR6-xlY3fpvVB4X6wpGSCY9D7p4VhPmdiSgJ6jLmOghuUOyO0Pd_ZKnX6t04rAgh2UvgckdttT9e1zX4eJwywH_gboXNwN_ie5QywAuyHF-gDrlch2_AvOvjPpoX1wIuMrx-z7qDoeT2QTuR8fTs3N4O_JH_WpjBa6nXPYbyfALTRVdVA |
linkProvider | Unpaywall |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3JbtQw1KqKUOGA2AkUMBKcaFRviZ0DQqVQTelyoC2aW-rYCUSKkmEm02okvolv5DlbGYFGXHqL4kW23_6e_R5Cr22UhVrqwLdRynwhIuaDGpIAXQmbUCNlljl_x9FxODoTn8fBeA396t_CuGuVPU9sGLWtjPORbzMFikcQKRW8n_zwXdUoF13tS2i0aHGQLi7BZJu92_8I8H3D2N6n092R31UV8E0gaO2bLCLG2EwHEhYZMWsSGQpiJLVUcxoyKgxLjbCR1NxwJhNDaAa0aBQzNHEOUGD5NwQnwuXql2M5-HRctnUlRPc2h3C1PRMNJwLBCIYaGAs-WZJ_TZmAf-m2f1_RHOK0t9HGvJzoxaUuij9E4d5ddKfTYfFOi3T30Fpa3kc326qWiwfo58nOlxN_t_rqM3yhjclbhyNOi9zk9Qwn00pbrEuLJxVo7DV81nlS2QVuL5dUU-ykbUMQuK5gDiCSEgZWGTbuleW0xHmJL-aFy5idFCnM01chmz1EZ9cCjkdovazK9AnCmU6zILDEcisElzbSMCxRllqireHaQ7Q_-th0GdBdIY4ibiLxXMUtuGIAV9yAKyYeejuMmbT5P1b2_uAgOvR0ububH9X0W9yxghjUEtiqyoRMXNTSKKmNZGFKdQi2rw09tNnjQ9wxlFl8hf4eejU0Aytw8R1dptW86SMVV0EAUzxu0WdYCcgRRjiXHlJLiLW01OWWMv_epBsHgx3MYgqb2-px8Gpdq85ia8DT_zi6p6t3_RJtjE6PDuPD_eODZ-gWcxRFgMeLTbReT-fpc1AN6-RFQ48YnV83A_gNalx2Tw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3JbtQw1KqK2A6InUABI8GJRhMviZ0DQqVl1FKoEKVobsaxE4gUJcNMptVIfBlfx3O2MgKNuPQ2mtiW7bcvfg-h5zbOIi106Ns4pT7nMfVBDUmArrhNiBEiy5y_48NRtH_C303CyQb61b-FcWmVPU9sGLWtjPORj6gExSOMpQxHWZcW8XFv_Hr6w3cdpFyktW-n0aLIYbo8A_Nt_upgD2D9gtLx28-7-37XYcA3ISe1b7I4MMZmOhSw4Zhak4iIB0YQSzQjESXc0NRwGwvNDKMiMQHJgC6NpIYkzhkK7P-SYJy5dDIxEYN_x1Vel5x373QCJkdz3nAlEJJgtIHh4AcrsrBpGfAvPffvdM0hZnsdXV2UU70800Xxh1gc30Q3On0W77QIeAttpOVtdLntcLm8g34e73w69nerLz7Fp9qYvHU-4rTITV7PcTKrtMW6tHhagfZew886Tyq7xG2iSTXDTvI2xIHrCtYAgilhYpVh415czkqcl_h0Ubjq2UmRwjp9R7L5XXRyIeC4hzbLqkwfIJzpNAtDG1hmOWfCxhqmJdISG2hrmPYQ6a9ema4aumvKUagmKs-kasGlAFyqAZcKPPRymDNta4GsHf3GQXQY6ep4N39Us2-qYwsKVBQ4qsy4SFwE00ihjaBRSnQEdrCNPLTV44PqmMtcnZOCh54Nn4EtuFiPLtNq0YwRkskwhCXut-gz7ARkCg0YEx6SK4i1stXVL2X-vSk9DsY7mMgEDrfd4-D5vtbdxfaAp_9xdQ_Xn_opugKkr94fHB0-QteoI6gA2D3fQpv1bJE-Bi2xTp405IjR14um_98HB3qK |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1rb9QwLBo3IcYH3o-DgYLEN9Zb82iTfjwmpgmJCTEOxqcqjxaqVe3prjd0iB-Pkz7gYJrYt6pxosSxYzt2bIRe2iSPlVBRYJOMBpwnNAA1RANfcauJESLP3X3Hu-P4aMbfnkanWyju38L4oH2f0tIf03102P6Se5YGCQMWD2jdQTiZ2_wa2o6dY2mEtmfH76dfXCW5kJMApDLrXsiETF7QeUMK-WT9F2mY_wZKDt7Sm-jGqpqr9XdVln8IpMPb6HO_lDYO5WyyavTE_Pgry-PV13oH3ep0VDxtIe-iray6h663VSvX99HPk-mHk-Cg_hRQfK6MKdoLRZyVhSmaJdaLWlmsKovnNWjkDXw2ha7tGrfBI_UCO2nqCR43NYwBTFBBxzrHxr2iXFS4qPD5qnQZsXWZwTh9lbHlAzQ7fPPx4CjoijgEJuKkCUyehMbYXEUCaCKh1mgR89AIYoliJKaEG5oZbhOhmGFUaBOSHI4-I6khmrGHaFTVVfYY4VxleRTZ0DLLORM2UdBNS0tsqKxhaoxIv6mp6TKcu0IbZeo97UymLWZTwGzqMZuGY_Rq6DNv83tcCv3a0coA6XJz-x_14mva7V8KagcsVeZcaOeVNFIoI2icERWDbWvjMdrtKS3tDoxlSiXo1VEiZTRGL4ZmYHXnv1FVVq88jJBMRhEM8aglzGEmICdoyJgYI7lBshtT3Wypim8-nTgY5GD2EljcXk_dv-d1GS72Bg74D9Q9uRr4U7RDHQOEcI7zXTRqFqvsGah_jX7e8fovSJ9VtQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SARS-CoV-2+vaccination+elicits+broad+and+potent+antibody+effector+functions+to+variants+of+concern+in+vulnerable+populations&rft.jtitle=Nature+communications&rft.au=Hederman%2C+Andrew+P&rft.au=Natarajan%2C+Harini&rft.au=Heyndrickx%2C+Leo&rft.au=Ari%C3%ABn%2C+Kevin+K&rft.date=2023-08-24&rft.pub=Nature+Publishing+Group&rft.eissn=2041-1723&rft.volume=14&rft.issue=1&rft.spage=5171&rft_id=info:doi/10.1038%2Fs41467-023-40960-0&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon |